Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - PREMIER BIOMEDICAL INC | Financial_Report.xls |
| EX-31.2 - CERTIFICATION - PREMIER BIOMEDICAL INC | premier_ex312.htm |
| EX-32.2 - CERTIFICATION - PREMIER BIOMEDICAL INC | premier_ex322.htm |
| EX-31.1 - CERTIFICATION - PREMIER BIOMEDICAL INC | premier_ex311.htm |
| EX-32.1 - CERTIFICATION - PREMIER BIOMEDICAL INC | premier_ex321.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Amendment No. 1)
(Mark One)
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended June 30, 2012
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from _______________ to _______________.
Commission file number: 000-54563
PREMIER BIOMEDICAL, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 27-2635666 | |
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
|
| 10805 Fallen Leaf Lane
Port Richey, FL
|
34668 | |
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code (814) 786-8849
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No x
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | o | Accelerated filer | o |
| Non-accelerated filer | o |
Smaller reporting company
|
x |
| (Do not check if a smaller reporting company) | |||
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes o No x
Applicable only to issuers involved in bankruptcy proceedings during the preceding five years:
Indicate by check mark whether the registrant filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes o No o
Applicable only to corporate issuers:
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of August 7, 2012, there were 11,701,190 shares of common stock, $0.00001 par value, issued and outstanding.
EXPLANATORY NOTE
The sole purpose of this Amendment No. 1 to Premier Biomedical, Inc's. Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2012, filed with the Securities and Exchange Commission on August 14, 2012 (the “Form 10-Q”), is to furnish Exhibit 101 in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language).
No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date and does not modify or update in any way disclosures made in the original Form 10-Q.
Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
ITEM 6 Exhibits
(a) Exhibits
|
3.1 (1)
|
Articles of Incorporation of Premier Biomedical, Inc.
|
|
3.2 (1)
|
Bylaws of Premier Biomedical, Inc.
|
|
3.3 (1)
|
Certificate of Designation of Series A Convertible Preferred Stock
|
|
10.1 (2)
|
Collaboration Agreement with the University of Texas System dated May 9, 2012.
|
|
31.1
|
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
|
|
31.2
|
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
|
|
32.1
|
Chief Executive Officer Certification Pursuant to 18 USC, Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
32.2
|
Chief Financial Officer Certification Pursuant to 18 USC, Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
101.INS**
|
XBRL Instance Document
|
|
101.SCH**
|
XBRL Schema Document
|
|
101.CAL**
|
XBRL Calculation Linkbase Document
|
|
101.DEF**
|
XBRL Definition Linkbase Document
|
|
101.LAB**
|
XBRL Labels Linkbase Document
|
|
101.PRE**
|
XBRL Presentation Linkbase Document
|
|
(1)
|
Incorporated by reference from our Registration Statement on Form S-1 dated June 13, 2011, filed with the Commission on June 14, 2011.
|
|
(2)
|
Incorporated by reference from our Current Report on Form 8-K dated May 9, 2012 and filed with the Commission on May 14, 2012.
|
** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
Premier Biomedical, Inc.
|
|||
|
Dated: August 16, 2012
|
/s/ William A. Hartman
|
||
| By: |
William A. Hartman
|
||
| Its: |
Chief Executive Officer
|
3